Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02321423
Other study ID # 20040468
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 2004
Est. completion date December 2030

Study information

Verified date November 2018
Source Pachyonychia Congenita Project
Contact Holly A Evans
Phone 8019878758
Email holly.evans@pachyonychia.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

International Pachyonychia Congenita Research Registry (IPCRR) is a patient registry for those suffering from Pachyonychia Congenita (PC). PC is an ultra-rare extremely painful skin disorder that causes painful blisters and callus on feet and sometimes hands, thickened nails, cysts and other features. The IPCRR consists of a questionnaire, patient photos, optional physician notes from telephone consultation to validate questionnaire and free genetic testing.


Description:

HOW TO PARTICIPATE IN IPCRR

Step One: The IPCRR forms are available online at http://www.pachyonychia.org/patient-registry/. The Consent Form protects your privacy and the Questionnaire gathers important details that distinguish PC from other conditions and helps to identify specific characteristics of each type of PC. You may stop and start as often as needed before completing the forms. If you are not certain about an answer, you may skip that question.

Step Two: Take photos as shown in the Questionnaire sample photo page. You can upload the images online with the Questionnaire. If you prefer, you may email the photos. Photos of your PC are very important. Note: If you do not have access to a computer and wish to have the IPCRR forms mailed, please contact PC Project.

Step Three: When your Consent Form, Questionnaire, and Photos are received by PC Project, we will have an intake call with you to review your information and to discuss the next steps.

Step Four: If referred for genetic testing, you will then be sent the special saliva test kit (no travel required). Usually, only saliva is needed and from only one family member. The sample is collected by spitting into the vial in the kit and then mailing it in the envelope provided. Genetic testing is complex and time-consuming — it is not like a sugar test or pregnancy test, and can take many months to be completed, but the testing begins as soon as your sample arrives.

When the confirming results are received, a full genetic testing report is provided to you with precise information and suggestions specific to your condition. You may find the report very valuable with physicians or other medical providers as well as for school personnel, employers, disability hearings, or other special needs. All information is held confidentially by PC Project and the research is reported anonymously. There is no cost to you for any of these tests or assistance from PC Project. You may also request additional consultations as needed.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date December 2030
Est. primary completion date December 2030
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Clinical diagnosis of Pachyonychia Congenita or similar disorder

Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Pachyonychia Congenita Project Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Pachyonychia Congenita Project

Country where clinical trial is conducted

United States, 

References & Publications (4)

Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol. 2012 Oct;67(4):680-6. doi: 10.1016/j.jaad.2011.12.009. Epub 2012 Jan 20. — View Citation

McLean WH, Hansen CD, Eliason MJ, Smith FJ. The phenotypic and molecular genetic features of pachyonychia congenita. J Invest Dermatol. 2011 May;131(5):1015-7. doi: 10.1038/jid.2011.59. Epub 2011 Mar 24. Review. — View Citation

Shah S, Boen M, Kenner-Bell B, Schwartz M, Rademaker A, Paller AS. Pachyonychia congenita in pediatric patients: natural history, features, and impact. JAMA Dermatol. 2014 Feb;150(2):146-53. doi: 10.1001/jamadermatol.2013.6448. — View Citation

Wilson NJ, O'Toole EA, Milstone LM, Hansen CD, Shepherd AA, Al-Asadi E, Schwartz ME, McLean WH, Sprecher E, Smith FJ. The molecular genetic analysis of the expanding pachyonychia congenita case collection. Br J Dermatol. 2014 Aug;171(2):343-55. doi: 10.1111/bjd.12958. Epub 2014 Aug 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Describing patterns and traits of Pachyonychia Congenita Once a year
See also
  Status Clinical Trial Phase
Completed NCT02592954 - Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin Phase 1
Active, not recruiting NCT04520750 - VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita Phase 3
Recruiting NCT05180708 - A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita Phase 3
Recruiting NCT05643872 - A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita Phase 3
Recruiting NCT05956314 - Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC Phase 1
Not yet recruiting NCT01382511 - Simvastatin Treatment of Pachyonychia Congenita N/A
Recruiting NCT05435638 - Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases Phase 1
Completed NCT02152007 - Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) Phase 1
Completed NCT00716014 - Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita Phase 1
Active, not recruiting NCT03920228 - Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita Phase 2/Phase 3